drugset / Trial / NCT06913075

FET in Adenomyosis

NCT06913075

Not yet recruiting 700 enrolled Indira IVF Hospital Pvt Ltd
RandomizedCrossoverOpen-labelTreatment

Summary

Purpose of the Study: To compare the effectiveness of GnRH agonist downregulation alone versus GnRH agonist combined with letrozole in improving pregnancy outcomes in women with adenomyosis undergoing frozen embryo transfer (FET). Research Question: Is the combined use of GnRH agonist and letrozole more effective than GnRH agonist downregulation alone in achieving better ongoing pregnancy rates in adenomyosis cases undergoing FET? Hypothesis: Null Hypothesis (H₀): The combined use of GnRH agonist and letrozole is not more effective than GnRH agonist downregulation alone in achieving a higher ongoing pregnancy rate in adenomyosis cases undergoing FET. Study Outcomes: Primary Outcome: Ongoing pregnancy rate at 12 weeks of gestation.

Timeline

Start
2026-06-25
Primary completion
2026-07-15
Completion
2026-12-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 5 mg
Comparator Triptorelin Other / unclassified 3.75 mg

Indications